Clinical Trials Logo

Clinical Trial Summary

To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2 with CLI.


Clinical Trial Description

To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2.

Diabetic patients will include with critical ischemia chronicle of at least a low member limb (CLI) and without possibilities of revascularization. 48 evaluable patients will be included, of which 36 patients will be included in the experimental group (12 for every cellular group) and 12 in the group control by conventional treatment. The population to studying will be constituted by 48 evaluable patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02287974
Study type Interventional
Source Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date September 2011
Completion date July 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03006770 - Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Phase 3
Completed NCT00987363 - Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization Phase 1/Phase 2
Not yet recruiting NCT02538978 - Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System Phase 3
Completed NCT01408381 - Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI). Phase 2
Active, not recruiting NCT05208905 - LIFE-BTK PK Sub-study N/A
Recruiting NCT04849325 - IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease N/A
Completed NCT01257776 - Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients Phase 1/Phase 2
Active, not recruiting NCT04227899 - LIFE-BTK Randomized Controlled Trial N/A
Terminated NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Phase 3
Terminated NCT03174522 - The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Phase 3
Completed NCT01386216 - Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) Phase 1
Available NCT03746899 - Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)
Available NCT03886506 - Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization